Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Longitudinal effects of ivacaftor and medicine possession ratio in people with the Gly551Asp mutation: a 5-year study.

Thorax - 1 Sept 2021

Mitchell Ruth Marian, Jones Andrew M, Stocking Katie, Foden Philip, Barry Peter J

Abstract excerpt

INTRODUCTION: Ivacaftor was the first therapy licensed to address the underlying defect in cystic fibrosis (CF). The improvements in lung function, nutritional status and pulmonary exacerbations in patients carrying a Gly551Asp mutation were greater than previously seen in clinical trials for other therapies. Limited data are available regarding long-term outcomes and adherence to ivacaftor outside clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aminophenols
Share to Chloride Channel Agonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Mutation

Share to Quinolones

Source

Identifiers

PMID: 33579778
DOI: 10.1136/thoraxjnl-2020-215556

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Longitudinal effects of ivacaftor and medicine possession ratio in people with the Gly551Asp mutation: a 5-year study.PMID 33579778Read ↗

Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease.Semantic proximity Read ↗

VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non-G551D-CFTR gating mutations.Semantic proximity Read ↗

Real-world impact of ivacaftor in people with cystic fibrosis and select ivacaftor-responsive mutations.Semantic proximity Read ↗

Tezacaftor-ivacaftor use in routine care of adults with cystic fibrosis: a medicine use evaluation.Semantic proximity Read ↗

Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis.Semantic proximity Read ↗

Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?Semantic proximity Read ↗

Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.Semantic proximity Read ↗

Ivacaftor: Five-year outcomes in the West of Scotland cystic fibrosis population.Semantic proximity Read ↗

Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.Semantic proximity Read ↗

Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.Semantic proximity Read ↗

Registry-based study in people with cystic fibrosis and an R117H variant treated with ivacaftor.Semantic proximity Read ↗

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.